Deferasirox (201530-41-8)

Deferasirox Chemical Structure

Home » APIs » Deferasirox

What is Deferasirox?

Deferasirox is a member of the class of triazoles. It is an iron chelator that can be taken orally and is marketed under the brand names Exjade & Asunra (for injectable formulation) & Oleptiss (for tablet formulation). It was approved by the U.S. Food and Drug Administration (FDA) in November 2005 for the treatment of chronic iron overload in patients receiving long term blood transfusions. It is also on the World Health Organization’s List of Essential Medicines.

Macsen Laboratories is the leading manufacturer and supplier of Deferasirox.
Name of Product Deferasirox
IUPAC Name 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid
Synonyms Exjade; Jadenu; Osveral; Déférasirox; Deferasiroxum
CAS No 201530-41-8
Molecular Formula C21H15N3O4
Molecular Weight 373.4 g/mol
Pubchem CID 214348

Chemical Properties

SR. No Criteria Limit/Specification
1 Appearance (Form) Solid Crystals or Powder
2 Appearance (Color) White to slightly yellow
3 Solubility Soluble in water (<1 mg/ml at 25° C), DMSO (75 mg/ml at 25° C), ethanol (2 mg/ml at 25° C), methanol, and ethyl acetate
4 Density 1.4±0.1 g/cm3
5 Melting Point 258-263° C

Mechanism of action

Some forms of blood disorders (such as sickle cell disease, anemia, thalassemia) typically necessitate frequent blood transfusions, which lead to an excess of iron content in the body. It is critical to eliminate excess iron since high amounts of iron can create health concerns (such as heart failure, liver disease, diabetes, and delayed growth in children). Deferasirox serves as an iron chelator. It binds to the iron molecule (Fe 3+) with high affinity in a 2:1 ratio and forms a stable complex, which is then excreted mainly in the stools.


  • Deferasirox is primarily used to reduce chronic iron overload in patients (in adults and children of 2 years of age and older) who are on blood transfusions from a long time for diseases like beta-thalassemia and other chronic anemias.
  • It is also used to treat people who have an excessive amount of iron in their bodies due to a genetic blood condition known as non–transfusion-dependent thalassemia (NTDT).
  • It is used in patients with elevated liver iron concentration and serum ferritin.

Side effects

The common side effects associated with the use of Deferasirox are-

  • Nausea
  • Vomiting
  • Skin rashes
  • Abdominal pain
  • Diarrhea

Serious side effects include-


Q. What is the difference between Deferasirox and Deferiprone?

Deferasirox and Deferiprone are oral iron-chelating agents used to treat chronic iron overload. However, Deferiprone is less expensive compared to Deferasirox and is superior in controlling or reducing myocardial iron load.

Q. What are the contraindications of using Deferasirox?

Deferasirox may cause fatal nephrotoxicity and is contraindicated for use in patients with renal failure or severe renal impairment. It is also contraindicated in patients suffering from hepatic disease and in those who are on anticoagulant therapy.

Q. What is the half life of Deferasirox?

Deferasirox has a dose-dependent plasma half-life of 12 to 18 hours and can be taken orally once a day after fasting on an empty stomach.

Buy high purity Deferasirox through Macsen Laboratories. For buying, send us an enquiry-

    Name (required)*

    Email (required)*

    Mobile No. (required)*

    Company Name (required)*

    Quantity & Packing Size Required


    You can enquire about any of our products/services online.

    Our team will get back to you within 24 hours.